Novo Nordisk’s Q1 results added momentum to its Wegovy pill strategy after the company adjusted its outlook around adjusted sales declines and adjusted operating profit. The update followed an improving commercial trajectory for the oral GLP-1 brand in the U.S., where Novo has faced competitive pressure from Eli Lilly’s obesity pipeline.